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Abstract 
Background: Immediate and late phases are known to be involved in the nasal 
symptoms of patients with allergic rhinitis. We examined the symptoms and mediators 
released following continuous allergen exposure in an environmental challenge chamber 
(ECC). 
Methods: Fifteen patients with Japanese cedar pollinosis were enrolled in this study and 
were continuously exposed to cedar pollen at a concentration of 8,000 grains/m³ for 3 h 
in an ECC. Nasal function tests were performed and nasal secretions were collected 
before pollen exposure (0 h), immediately after exiting the ECC (3 h), and 6 h after 
exiting (9 h). Symptom scores were recorded every 30 min in the ECC and every 3 h 
after exiting the ECC. The frequencies of sneezing and nose blowing were also 
monitored. 
Results: The severity of symptoms in the ECC peaked approximately 2 h after the 
beginning of pollen exposure and continued for >6 h after leaving the ECC. The 
concentrations of histamine, tryptase, interleukin (IL)-5, IL-13, IL-33, IL-31, and 
substance P increased with time, but that of the nasal fractional exhaled nitric oxide 
decreased. 
Conclusion: Various mediators were released during continuous allergen exposure and 
induced persistent nasal symptoms. Thus, an effective treatment is required to control 
the intense inflammation observed following allergen exposure. 
Introduction 
Nasal symptoms in patients with allergic rhinitis (AR) are observed after nasal 
provocation with allergen-coated disks or nasal spray and are comprised of immediate 
and late phases1-4. Histamine released from mast cells plays an important role in the 
immediate-phase reaction and induces sneezing, rhinorrhea, and some degree of nasal 
congestion. This reaction occurs within 15 min after antigen exposure and persists for 
only a short time1. Leukotrienes released from infiltrating eosinophils are mainly 
involved in the late-phase reaction that occurs several hours after antigen exposure and 
induces nasal congestion4. However, it is difficult to evaluate the two phases separately 
in patients under natural exposure to allergens in daily life, and different 
pathophysiological changes could be observed. 
An environmental challenge chamber (ECC) can be used to expose subjects to the 
same amount of pollen in a stable atmosphere and thus may be useful to evaluate the 
pathophysiology of AR5. Continuous pollen exposure in the ECC can induce symptoms 
mimicking those observed naturally during the pollen season. Particularly, Japanese 
cedar (Cryptomeria japonica) pollen is the most common allergen associated with 
seasonal AR in Japan6. Our group previously established an experimental method to 
monitor pollen distribution and exposure using the ECC to evaluate Japanese cedar 
pollinosis and have reported our results in two previous clinical studies7, 8. 
In the present study, we conducted a continuous 3 h cedar pollen exposure in patients 
with cedar pollinosis using the ECC and carefully examined the symptoms, 
physiological changes, and various mediators in nasal secretions. 
 
 
Materials and Methods 
Subjects 
We recruited 15 subjects (mean age, 37.8 ± 10.3 years) with a history of rhinitis due to 
Japanese cedar pollinosis for at least two consecutive cedar pollen seasons and who met 
the following inclusion criteria: positive allergen-specific skin test (wheal diameter 
more than twice that of the control or >5 mm) to standardized cedar pollen extract (Torii 
Pharmaceutical Co., Ltd., Tokyo, Japan) and a serum cedar pollen-specific IgE score ≥2 
on a fluorescent enzyme immunoassay (SRL Hachioji Laboratories, Tokyo, Japan). 
Exclusion criteria were nasal disease, including AR caused by other allergens that 
required treatment, severe asthma, use of anti-allergic drugs within 4 weeks of the study, 
pregnancy, possibility of pregnancy, and currently lactating. This study protocol was 
approved by the ethics committee of Chiba University, Graduate School of Medicine 
(approval number: 1412), and written informed consent was obtained from all subjects.  
 
ECC 
The examination was conducted in the ECC at Chiba University, which can 
accommodate up to 50 subjects. As we reported previously5, the concentration of 
Japanese cedar pollen was set to 8,000 grains/m³. The pollen concentration in the air 
was monitored every 5 min using an automatic pollen measuring instrument (Shinyei 
Kaisha, Kobe, Japan). We previously confirmed that symptoms of Japanese cedar 
pollinosis peak within 3 h at this pollen concentration. The symptoms of all subjects in 
the ECC were recorded using a mobile communication device (Willcom, Inc., Tokyo, 
Japan). 
 
Study protocol 
A schematic representation of the study protocol is shown in Figure 1. This study was 
planned to avoid the 2012 pollen dispersal season. All 15 subjects were exposed to 
cedar pollen at a concentration of 8,000 grains/m³ for 3 h in the ECC. Nasal symptoms 
were evaluated during active pollen exposure and after exiting the ECC. The 
frequencies of sneezing, nose blowing, and severity of nasal symptoms (e.g., sneezing, 
rhinorrhea, and nasal congestion) were recorded every 30 min in the ECC using a 
mobile communication device. Also, the subjects had to self-record nasal symptoms 3, 6, 
and 9 h after exiting the ECC using an allergy diary. The frequencies of sneezing and 
nose blowing were also recorded every 3 h. We measured the nasal fractional exhaled 
nitric oxide (FeNO) and nasal airway resistance, and obtained nasal secretion and nasal 
lavage measurements before the study subjects entered the ECC, immediately after 
exiting, and 6 h after exiting. 
 
Scoring of nasal symptoms 
The severity of the three surveyed symptoms was evaluated on a 4-point scale (range, 
0–3) and defined as follows: 0, none; 1, mild; 2, moderate; and 3, severe. The total nasal 
symptom score (TNSS) was defined as the sum of these scores (range, 0–9).  
 
Nasal FeNO 
Nasal FeNO level was measured according to the American Thoracic Society/European 
Respiratory Society guidelines9 using a hand-held electrochemical analyzer (NObreath; 
Bedfont Scientific Ltd., Kent, UK). The subjects were instructed to inhale ambient air to 
near total lung capacity and then exhale transnasally through a nosepiece connected to 
the device. Flow rate was set to 50 mL/s, and duration was 16 s. Each measurement was 
performed twice, and the mean value was used for analysis10. 
 
Nasal airway resistance 
Rhinomanometry was performed to examine nasal airway resistance. Bilateral nasal 
resistance at ΔP100 Pa was measured by active anterior rhinomanometry with a nasal 
nozzle attached to a rhinorheograph (MPR-3100; Nihon-Kohden, Tokyo, Japan), and 
total nasal resistance was calculated as the sum of the bilateral rhinomanometry 
recordings11, 12. 
 
Measurement of mediators in nasal secretions 
The IVALON 4000 plus surgical sinus pack (80 × 15 × 20 mm; First Aid Bandage Co, 
New London, CN, USA) was inserted gently into each common nasal meatus, removed 
after 10 min, placed into the shaft of a 5-mL syringe (Terumo Corp,, Tokyo, Japan), and 
the syringe was inserted into a 15-mL Falcon tube (BD Biosciences, Franklin Lakes, NJ, 
USA). The mass of the collected secretions was calculated by comparing the weight of 
the sinus pack with those of the Falcon tube and syringe shaft before and after insertion 
using the same balance (Mettler Toledo, Columbus, OH, USA); 1 g of nasal secretions 
was considered 1 mL. After weighing the samples, 3 mL of sterile physiological saline 
solution was placed on the sinus pack. Then, the Falcon tube containing the shaft with 
the sinus pack was centrifuged at 1,500 × g for 10 min at 4°C to extract the nasal 
secretions13. Aliquots of 500 μL each were prepared and stored at −80°C for further 
analysis.  
Interleukin (IL)-4, IL-5, IL-13, and interferon (IFN)-γ levels were measured using the 
Cytometric Bead Array kit (BD Biosciences), according to the manufacturer’s 
instructions. IL-31 and IL-33 concentrations were measured using enzyme-linked 
immunosorbent assay kits according to the manufacturer’s instructions (PeproTech, 
Rocky Hill, NJ, USA). Histamine, tryptase, leukotriene, and eosinophilic cationic 
protein (ECP) concentrations were measured by SRL Hachioji Laboratories, and 
substance P was measured by Kyowa Hakko Kirin Co., Ltd. (Tokyo, Japan). 
 
Immunohistochemical staining of cells infiltrating nasal lavage fluid 
Nasal lavage was performed by irrigating 5 mL of physiological saline into each nasal 
cavity while the subject was in the hanging head position and repeating the “k-k-k” 
sound multiple times to close the soft palate and minimize fluid running into the throat14. 
When appropriate, nasal lavage fluid was collected using a suction kit (MD-33030, 
Sumitomo Bakelite Co., Ltd., Tokyo, Japan). Mucin was removed through a 70-μm cell 
strainer (BD Biosciences) and centrifuged at 1500 rpm for 5 min at 4°C. The samples 
were centrifuged again at 3000 rpm for 5 min at 4°C to obtain single-cell suspensions (5 
× 105 cells/mL). The single-cell suspensions were mounted on Cytospin slides and 
stored at −80°C for future immunohistochemical staining. 
The Cytospin slides were fixed in cold acetone for 10 min, washed with 
phosphate-buffered saline, and stained with the anti-basophil antibody 2D7 (Abcam Plc, 
Cambridge, MA, USA) followed by anaphase-promoting complex-coupled anti-mouse 
antibody (BioLegend, Inc., San Diego, CA, USA). Nuclei were stained with 
TO-PRO®-3 Iodide (Invitrogen, Carlsbad, CA, USA). All slides were assessed using a 
LSM700 scanning laser confocal microscope and imaging software (Zen 2011; Carl 
Zeiss MicroImaging GmbH, Jena, Germany). 
 Statistical analysis 
All statistical analyses were performed using the two-tailed Wilcoxon signed-rank test. 
Data are presented as means ± 95% confidence intervals. A correlation analysis was 
performed using the Spearman’s rank correlation coefficient. A probability (p) value < 
0.05 was considered statistically significant. 
 
Results 
Changes in nasal symptoms  
The severity of each symptom and TNSS are shown in Figure 2. All symptom scores 
increased gradually and reached a plateau approximately 2 h after initial pollen 
exposure. Sneezing, rhinorrhea, and congestion persisted after the subjects exited the 
ECC. The frequencies of sneezing and nose blowing are shown in Figure 3. Notably, 
sneezing and rhinorrhea persisted in the subjects after exiting the ECC.  
 
Nasal physiological function tests 
The 0, 3, and 9 h time points in the figures represent the time before pollen exposure, 
immediately after exiting the ECC, and 6 h after exiting the ECC, respectively. Nasal 
airway resistance at 3 and 9 h was significantly higher than that at 0 h. No significant 
difference was observed between the 3 and 9-h measurements (Figure 4A). As shown in 
Figure 4B, nasal FeNO values at 3 and 9 h were significantly lower than that at 0 h, 
whereas no significant difference was observed between the values recorded at 3 and 9 
h.  
 
Mediators of nasal secretion  
As shown in Figure 5B–E, IL-5, IL-13, IL-31, and IL-33 levels were significantly 
elevated with elapsed time. The IL-4 level at 9 h was significantly higher than that at 0 h, 
whereas no significant differences were observed among the other time points (Figure 
5A), and no significant difference was detected in IFN-γ levels (Figure 5F). Leukotriene, 
ECP, histamine, and substance P levels also increased significantly with elapsed time 
(Figure 5G–I, K). Tryptase levels at 3 and 9 h increased significantly compared with 
those at 0 h, whereas no significant difference was observed between the values at 3 and 
9 h (Figure 5J).  
 
Immunohistochemical staining of cells infiltrating the nasal lavage fluid 
Although it was difficult to identify basophils in nasal lavage fluid collected from the 
subjects immediately after exiting the ECC (Figure 6A), basophil (2D7-positive cells) 
infiltration into nasal lavage fluid was confirmed 6 h after exiting the ECC (Figure 6B).  
 
Correlations between nasal symptoms and chemical mediators in nasal secretions 
The histamine, substance P and IL-31 concentration at 9 h was significantly correlated 
with the total number of sneezing and nose-blowing episodes from 6 to 12 h (Figure 
7A-C).  
 
Discussion 
We found that not only nasal obstruction but also sneezing and rhinorrhea persisted 
after the 3-h pollen exposure period in the ECC. The severities of these symptoms 
observed at 6 h after exiting the ECC were almost the same as those immediately 
following the 3 h pollen exposure. 
Histamine is released from mast cells or by basophil degranulation and acts on H1 
receptors to induce vascular permeability and activate nociceptive nerves that recruit 
parasympathetic reflexes. Thus, activation of nociceptive nerves may induce the axon 
response-mediated release of neuropeptides, such as substance P15.  
Tryptase is a serine protease component of mast cell granules. Although the quantity 
of tryptase is much less than that in mast cells, basophils also release tryptase during 
degranulation16. Although a quantitative analysis of markers in nasal secretions is 
difficult, in this study a significant number of basophils were observed in the nasal 
secretions of all subjects collected 6 h after exiting the ECC. Basophils as well as mast 
cells present the high-affinity IgE receptor and are activated by cross-linking with 
antigens through IgE, followed by histamine release. Mast cell and basophil 
degranulation also occurs directly in response to various IgE-independent stimuli, such 
as substance P and IL-3317-19. In our study, concentrations of histamine and tryptase 
increased with time along with those of IL-5, IL-13, IL-33, IL-31, and substance P. 
Histamine released both dependently and independently by IgE induces sneezing and 
other nasal symptoms. In addition, basophils significantly increase levels of Th2 
cytokines and aggravate allergic reactions by several mechanisms.  
Sneezing and other symptoms are induced by histamine and other mediators, such as 
substance P and IL-31 which are markedly released by Th2 cells and directly stimulate 
sensory nerve fibers, resulting in a sensation of itching in patients with atopic 
dermatitis20-23. Although the role of IL-31 in AR is not well defined, it may induce nasal 
itching and sneezing. Moreover, Baumann et al.24 reported that IL-31 levels in nasal 
secretions increased by 5 h after a single nasal allergen challenge, which was correlated 
with nasal symptom score. In our study, the histamine, substance P and IL-31 
concentration at 9 h was significantly correlated with the total number of sneezing and 
nose-blowing episodes from 6 to 12 h. These results support past reports. 
Leukotrienes act on leukotriene receptors 1 and 2 on vessels in the nasal mucosa and 
obstruct the nasal passages 24, 25. In the present study, an increase in concentrations of 
leukotrienes was observed, which may have contributed to nasal obstruction even 
though many other mediators participate in nasal obstruction. However, the 
concentration of nasal NO was not correlated with nasal symptom severity including 
nasal obstruction and even decreased with time under increased allergic inflammation. 
NO is produced by inducible nitric oxide synthase (NOS) in inflammatory cells and is a 
useful inflammation marker in the lower airway26. Endothelial NOS in the parasinus 
mucosa of the upper airway produces a high NO concentration27. Swelling of nasal 
mucosa and nasal secretions caused by pollen exposure would obliterate the orifice of 
the sinus mucosa to the nasal cavity and as a result decrease the concentration of nasal 
NO. 
IL-33 is one of the many representative cytokines produced in airway epithelium that 
induces allergic inflammation following allergen exposure or in an IgE-independent 
manner28. This inflammatory molecule exists in epithelial cells and is released 
extracellularly upon stimulation or damage caused by various antigens or pathogens, 
such as pollens, mites, and microbes. Moreover, IL-33 may play an important role in the 
initiation, amplification, and maintenance of Th2-skewed allergic inflammation. We 
found pathogenic Th2 cells in eosinophilic inflammation in the respiratory tract of mice 
produce large quantities of Th2 cytokines compared with those by conventional memory 
Th2 cells after synergistic stimulation of IL-33 with specific antigens29. Pathogenic Th2 
cells may be involved in the development and progression of AR. 
During the pollen dispersal season, patients may suffer from indoor nasal symptoms, 
including sneezing and rhinorrhea as well as sleep disturbances, even though the 
number of pollen grains is minimal. Patients often develop severe symptoms even 
during rainy days. Such symptoms can result from even minimal persistent 
inflammation of the nasal mucosa. Furthermore, allergic inflammation induced by the 
extensive allergic reaction due to outdoor pollen exposure often persists for extended 
periods. In the present study, intensive inflammation was induced in the nasal mucosa 
during continuous pollen exposure in the ECC, and the nasal symptoms including 
sneezing persisted after leaving the chamber. This study was conducted outside of the 
pollen dispersal season, and the subjects used disposable overalls, hair caps, and shoes 
in the ECC, which they took off when they left in order to not carry the pollen outside. 
Besides, any pollen would exit the nasal cavity after the subjects left the ECC because 
of the nasal lavage. In previous similar studies conducted using an ECC, we found that 
nasal symptoms persisted for 2 days after a 3 h pollen exposure7. A more severe change 
may occur under natural continuous allergen exposure. Thus, developing an effective 
treatment for the intense inflammation observed after continuous allergen exposure in 
the nasal mucosa is of critical importance. 
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Figure legends  
Figure 1. Study protocol  
Various examinations [rhinomanometry, nasal fractional exhaled nitric oxide (FeNO), 
nasal secretion collection, and nasal lavage] were performed before entering, 
immediately after exiting, and 6 h after exiting the environmental challenge chamber 
(ECC). Symptom scores were recorded every 30 min in the ECC and every 3 h after 
exiting the ECC. The frequencies of sneezing and nose blowing were recorded every 3 
h. 
 
Figure 2. Changes in nasal symptoms.  
(A) Total nasal symptoms. (B) Sneezing. (C) Rhinorrhea. (D) Nasal congestion. Values 
are presented as means ± 95% confidence intervals. 
 
Figure 3. Frequencies of sneezing and nose blowing.  
(A) Sneezing frequency. (B) Nose blowing frequency. Values are presented as means ± 
95% confidence intervals. 
 
Figure 4. Nasal physiological function tests. 
(A) Nasal airway resistance. (B) Nasal fractional exhaled nitric oxide (FeNO). Values 
are presented as means ± 95% confidence intervals (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). 
 
Figure 5: Mediators in nasal secretions. 
(A) Interleukin (IL)-4. (B) IL-5. (C) IL-13. (D) IL-31. (E) IL-33. (F) Interferon (IFN)-γ. 
(G) Leukotrienes. (H) Eosinophilic cationic protein. (I) Histamine. (J) Tryptase. (K) 
Substance P. Values are presented as means ± 95% confidence intervals (∗p < 0.05, ∗∗p < 
0.01, ∗∗∗p < 0.001). 
 
Figure 6. Immunohistochemical staining of cells infiltrating the nasal lavage fluid. 
(A) Immediately after exiting the environmental challenge chamber (ECC) (3 h). (B) 6 h 
after exiting the ECC (9 h). Infiltration of basophils (2D7-positive cells) was confirmed 
6 h after exiting the ECC. 
 
Figure 7. Correlations between nasal symptoms and chemical mediators in nasal 
secretions. 
The histamine (A), substance P (B) and IL-31 (C) concentration at 9 h was significantly 
correlated with the total number of sneezing and nose-blowing episodes from 6 to 12 h. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Journal of Allergy and Clinical Immunology 
平成 27年 1月 投稿中 
